Medtronic Statement Regarding Revised IN.PACT Post Market Study Data
(WorldNews Africa)

Medtronic Statement Regarding Revised IN.PACT Post Market Study Data DUBLIN - February 15, 2019 - Medtronic plc (NYSE:MDT) today issued the following statement regarding revised clinical study data: Recently, Medtronic became aware of a programming error in the clinical data reporting isolated to the two- and three-year follow-up periods in our IN.PACT Global post-market study, part of the IN.PACT Admiral clinical program for the treatment of femoropopliteal artery disease. Preliminary results of this study were first released at the Leipzig Interventional Course (LINC) and Medtronic issued a press release summarizing the results on January 22, 2019. Due to a...